• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Monday's Intraday Session

    7/31/23 1:31:28 PM ET
    $ADIL
    $APLS
    $BJDX
    $BNOX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ADIL alert in real time by email

    Gainers

    • Mallinckrodt (AMEX:MNK) stock rose 41.7% to $1.53 during Monday's regular session. Trading volume for this security as of 13:31 EST is 14.8 million, which is 377.2% of its average full-day volume over the last 100 days. The company's market cap stands at $20.1 million.
    • GoodRx Holdings (NASDAQ:GDRX) stock moved upwards by 34.8% to $9.1. As of 13:31 EST, this security is trading at a volume of 17.8 million shares, making up 1432.5% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $3.6 billion.
    • SmileDirectClub (NASDAQ:SDC) stock rose 22.42% to $0.86. SmileDirectClub's stock is trading at a volume of 8.0 million shares as of 13:31 EST. This is 568.4% of its average full-day volume over the last 100 days. The company's market cap stands at $113.5 million.
    • Enochian BioSciences (NASDAQ:ENOB) stock increased by 21.34% to $0.69. Trading volume for this security as of 13:31 EST is 251.7K, which is 102.8% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $44.0 million.
    • Better Therapeutics (NASDAQ:BTTX) shares moved upwards by 19.19% to $0.74. Trading volume for Better Therapeutics's stock is 2.0 million as of 13:31 EST. This is 247.3% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $24.9 million.
    • Adial Pharmaceuticals (NASDAQ:ADIL) stock rose 18.35% to $0.32. The current volume of 1.4 million shares is 60.3% of Adial Pharmaceuticals's average full-day volume over the last 100 days (last updated at 13:31 EST). The company's market cap stands at $9.6 million.

    Losers

    • Marker Therapeutics (NASDAQ:MRKR) shares fell 23.6% to $4.94 during Monday's regular session. Trading volume for this security as of 13:31 EST is 335.5K, which is 38.0% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $43.4 million.
    • OKYO Pharma (NASDAQ:OKYO) stock declined by 22.28% to $1.71. OKYO Pharma's stock is trading at a volume of 375.0K shares as of 13:31 EST. This is 227.6% of its average full-day volume over the last 100 days. The company's market cap stands at $43.6 million.
    • Apellis Pharmaceuticals (NASDAQ:APLS) shares fell 20.59% to $25.43. Apellis Pharmaceuticals's stock is trading at a volume of 15.0 million shares as of 13:31 EST. This is 498.1% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $2.9 billion. As per the press release, Q2 earnings came out today.
    • Bluejay Diagnostics (NASDAQ:BJDX) shares fell 17.63% to $6.45. The current volume of 288.9K shares is 74.4% of Bluejay Diagnostics's average full-day volume over the last 100 days (last updated at 13:31 EST). The market value of their outstanding shares is at $6.6 million.
    • Checkpoint Therapeutics (NASDAQ:CKPT) shares declined by 16.46% to $2.59. As of 13:31 EST, Checkpoint Therapeutics's stock is trading at a volume of 985.4K, which is 463.4% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $44.7 million.
    • Bionomics (NASDAQ:BNOX) stock declined by 11.52% to $1.69. The market value of their outstanding shares is at $13.7 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ADIL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADIL
    $APLS
    $BJDX
    $BNOX

    CompanyDatePrice TargetRatingAnalyst
    GoodRx Holdings Inc.
    $GDRX
    2/27/2026Overweight → Neutral
    Analyst
    OKYO Pharma Limited
    $OKYO
    2/20/2026$7.00Overweight
    Piper Sandler
    Apellis Pharmaceuticals Inc.
    $APLS
    1/28/2026$24.00Equal Weight
    Barclays
    GoodRx Holdings Inc.
    $GDRX
    1/22/2026$2.75Buy → Hold
    Jefferies
    Apellis Pharmaceuticals Inc.
    $APLS
    1/21/2026$28.00Neutral → Buy
    BofA Securities
    GoodRx Holdings Inc.
    $GDRX
    12/9/2025$3.00Underweight
    Barclays
    OKYO Pharma Limited
    $OKYO
    12/8/2025$5.00Buy
    B. Riley Securities
    Apellis Pharmaceuticals Inc.
    $APLS
    11/6/2025Peer Perform
    Wolfe Research
    More analyst ratings

    $ADIL
    $APLS
    $BJDX
    $BNOX
    SEC Filings

    View All

    SEC Form PRE 14A filed by Marker Therapeutics Inc.

    PRE 14A - Marker Therapeutics, Inc. (0001094038) (Filer)

    3/10/26 4:59:15 PM ET
    $MRKR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    GoodRx Holdings Inc. filed SEC Form 8-K: Leadership Update

    8-K - GoodRx Holdings, Inc. (0001809519) (Filer)

    3/6/26 4:38:47 PM ET
    $GDRX
    EDP Services
    Technology

    SEC Form 10-K filed by Bluejay Diagnostics Inc.

    10-K - Bluejay Diagnostics, Inc. (0001704287) (Filer)

    3/6/26 4:02:15 PM ET
    $BJDX
    Medical/Dental Instruments
    Health Care

    $ADIL
    $APLS
    $BJDX
    $BNOX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Elms Steve bought $35,472 worth of shares (11,085 units at $3.20) (SEC Form 4)

    4 - Marker Therapeutics, Inc. (0001094038) (Issuer)

    12/26/24 4:01:17 PM ET
    $MRKR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner New Enterprise Associates 16, L.P. bought $1,773,600 worth of shares (554,250 units at $3.20) (SEC Form 4)

    4 - Marker Therapeutics, Inc. (0001094038) (Issuer)

    12/23/24 4:40:48 PM ET
    $MRKR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dey Svetlana bought $1,535 worth of shares (500 units at $3.07), increasing direct ownership by 50% to 1,500 units (SEC Form 4)

    4 - Bluejay Diagnostics, Inc. (0001704287) (Issuer)

    12/14/23 4:17:42 PM ET
    $BJDX
    Medical/Dental Instruments
    Health Care

    $ADIL
    $APLS
    $BJDX
    $BNOX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for EMPAVELI issued to APELLIS PHARMACEUTICALS INC

    Submission status for APELLIS PHARMACEUTICALS INC's drug EMPAVELI (ORIG-1) with active ingredient PEGCETACOPLAN has changed to 'Approval' on 05/14/2021. Application Category: NDA, Application Number: 215014, Application Classification: Type 1 - New Molecular Entity

    5/17/21 11:09:40 AM ET
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADIL
    $APLS
    $BJDX
    $BNOX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    GoodRx Partners with Viatris to Offer Up to 85% Savings on Established Brand Medications

    Collaboration expands access to trusted therapies with discounted cash prices for leading brands including Lipitor®, Celebrex®, Viagra®, and Norvasc® GoodRx (NASDAQ:GDRX), the leading platform for prescription savings in the U.S., today announced a new collaboration with Viatris, a global healthcare company, to make 17 of its established brand medications more affordable for consumers. Beginning today, eligible commercially insured patients may pay as low as $0–$4 on select Viatris medications through GoodRx. Cash-paying consumers, regardless of insurance status, can use GoodRx to access discounted cash prices of up to 85% off at more than 70,000 pharmacies nationwide. The collaboration i

    3/11/26 9:00:00 AM ET
    $GDRX
    EDP Services
    Technology

    GoodRx to Expand Employer-Sponsored Access to Zepbound® KwikPen®

    GoodRx Employer Direct enables self-insured employers to subsidize the $449 Lilly Employer Connect medication price for Zepbound KwikPen to reduce employee out-of-pocket costs Brief Summary: GoodRx to collaborate with Eli Lilly to expand employer-sponsored access to Zepbound® KwikPen®, an FDA-approved dual GIP and GLP-1 obesity treatment Through GoodRx Employer Direct, self-insured employers can subsidize Lilly's $449 discounted medication price for Zepbound KwikPen Employer contributions are applied to the medication cost, reducing employee out-of-pocket costs GoodRx integrates manufacturer discounted pricing and employer funding in real time; optional telemedicine supports p

    3/6/26 9:00:00 AM ET
    $GDRX
    EDP Services
    Technology

    Adial Pharmaceuticals Reports 2025 Fiscal Year Financial Results and Provides Business Update

    GLEN ALLEN, Va., March 06, 2026 (GLOBE NEWSWIRE) --  Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the 2025 fiscal year ended December 31, 2025. Key Highlights: Regulatory Progress: Achieved positive clinical study results from the AD04-103 pharmacokinetics (PK) study supporting AD04's pharmacologic profile and regulatory strategy.Received a positive response from the U.S. Food and Drug Administration (FDA) regarding the Company's proposed in vitro bri

    3/6/26 8:00:00 AM ET
    $ADIL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADIL
    $APLS
    $BJDX
    $BNOX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Accounting Officer Nabiey Romin converted options into 12,434 shares and covered exercise/tax liability with 5,121 shares, increasing direct ownership by 4% to 183,061 units (SEC Form 4)

    4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

    3/9/26 5:19:20 PM ET
    $GDRX
    EDP Services
    Technology

    SEC Form 4 filed by Officer Mcginnis Christopher A

    4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

    3/5/26 8:11:56 PM ET
    $GDRX
    EDP Services
    Technology

    SEC Form 4 filed by Chief Accounting Officer Nabiey Romin

    4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

    3/5/26 8:09:58 PM ET
    $GDRX
    EDP Services
    Technology

    $ADIL
    $APLS
    $BJDX
    $BNOX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    GoodRx downgraded by Analyst

    Analyst downgraded GoodRx from Overweight to Neutral

    2/27/26 8:28:37 AM ET
    $GDRX
    EDP Services
    Technology

    Piper Sandler initiated coverage on OKYO Pharma with a new price target

    Piper Sandler initiated coverage of OKYO Pharma with a rating of Overweight and set a new price target of $7.00

    2/20/26 8:25:04 AM ET
    $OKYO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Barclays initiated coverage on Apellis Pharmaceuticals with a new price target

    Barclays initiated coverage of Apellis Pharmaceuticals with a rating of Equal Weight and set a new price target of $24.00

    1/28/26 7:15:29 AM ET
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADIL
    $APLS
    $BJDX
    $BNOX
    Leadership Updates

    Live Leadership Updates

    View All

    Apellis Announces Mikael Dolsten, M.D., Ph.D., to Join Board of Directors

    WALTHAM, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) announced today that Mikael Dolsten, M.D., Ph.D., has joined the company's board of directors as of March 1. Most recently, Dr. Dolsten served for more than 16 years as chief scientific officer and president, worldwide research, development and medical, at Pfizer, during which he presided over the regulatory approval of more than 36 medicines and vaccines.  "We are thrilled to welcome Mikael to the Apellis Board of Directors," said Cedric Francois, M.D., Ph.D., chief executive officer and co-founder, Apellis. "Mikael is a proven industry leader with deep experience developing innovative medicine

    3/2/26 7:00:00 AM ET
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    OKYO Pharma Strengthens World Class Leadership Team with Appointment of Flavio Mantelli, MD, PhD as Chief Medical Officer

    Dr. Mantelli, former Chief Medical Officer at Dompé, spearheaded the successful clinical development program and FDA approval of Oxervate®, a blockbuster orphan therapy in corneal diseaseDr. Mantelli will lead the clinical and regulatory strategy to advance the company's development program in neuropathic corneal pain (NCP), leveraging urcosimod's FDA Fast Track designationThis appointment, following the recent CEO appointment, further strengthens OKYO's world-class ophthalmology leadership team LONDON and NEW YORK, Feb. 10, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neur

    2/10/26 8:00:00 AM ET
    $OKYO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    TTM Technologies, Dutch Bros, Advanced Energy Industries, and American Healthcare REIT Set to Join S&P MidCap 400; Others to Join S&P SmallCap 600

    NEW YORK, Jan. 27, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400, S&P SmallCap 600: S&P SmallCap 600 constituent TTM Technologies Inc. (NASD: TTMI) will replace Civitas Resources Inc. (NYSE:CIVI) in the S&P MidCap 400, and Amneal Pharmaceuticals Inc. (NASD: AMRX) will replace TTM Technologies in the S&P SmallCap 600 effective prior to the opening of trading on Friday, January 30. S&P SmallCap 600 constituent SM Energy Co. (NYSE:SM) is acquiring Civitas Resources in a deal expected to be completed soon, pending final closing conditions. SM Energy will remain in the S&P SmallCap 600 post-merger.Dutch Bros Inc. (NYSE:BROS) will replace Potlatc

    1/27/26 6:02:00 PM ET
    $AEIS
    $AHR
    $AMRX
    Industrial Machinery/Components
    Technology
    Real Estate Investment Trusts
    Real Estate

    $ADIL
    $APLS
    $BJDX
    $BNOX
    Financials

    Live finance-specific insights

    View All

    Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

    Full-year 2025 net product revenues of $689 million SYFOVRE® (pegcetacoplan injection) full year 2025 net product revenue of $587 millionEMPAVELI® (pegcetacoplan) full year 2025 net product revenue of $102 million Regulatory submission for SYFOVRE prefilled syringe planned for the first half of 2026EMPAVELI franchise has strong momentum with successful launch in C3G and primary IC-MPGN, and pivotal trials underway in FSGS and DGFCash and cash equivalents of $466 million as of December 31, 2025; projected revenues, cash, and cash equivalents expected to be sufficient to fund operations to profitabilityManagement to host conference call today at 8:30 a.m. ET WALTHAM, Mass., Feb. 24, 2026 (G

    2/24/26 7:05:00 AM ET
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Apellis Pharmaceuticals to Host Conference Call on February 24, 2026, to Discuss Fourth Quarter and Full Year 2025 Financial Results

    WALTHAM, Mass., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) today announced that the company will host a conference call and webcast to discuss its fourth quarter and full year 2025 financial results on Tuesday, February 24, 2026 at 8:30 a.m. ET. To access the live call by phone, please pre-register for the call here. A live audio webcast of the event and accompanying slides may also be accessed through the "Events and Presentations" page of the "Investors and Media" section of the company's website. A replay of the webcast will be available for 30 days following the event. About Apellis Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company

    2/10/26 7:00:00 AM ET
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    GoodRx Announces Date for Fourth Quarter and Full Year 2025 Earnings Release and Conference Call

    GoodRx Holdings, Inc. (NASDAQ:GDRX) ("GoodRx" or the "Company"), the leading platform for prescription savings in the U.S., today announced it will release its fourth quarter and full year 2025 financial results after U.S. markets close on Wednesday, February 25, 2026. GoodRx management will also hold a conference call and webcast the following morning, Thursday, February 26, 2026 at 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) to discuss the results and the Company's business outlook. To access the conference call, please pre-register using this link. Registrants will receive a confirmation with dial-in details and a unique passcode required to join. The call will also be webcast live

    1/28/26 4:05:00 PM ET
    $GDRX
    EDP Services
    Technology

    $ADIL
    $APLS
    $BJDX
    $BNOX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Apellis Pharmaceuticals Inc.

    SC 13G/A - Apellis Pharmaceuticals, Inc. (0001492422) (Subject)

    11/22/24 4:16:13 PM ET
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Apellis Pharmaceuticals Inc.

    SC 13G - Apellis Pharmaceuticals, Inc. (0001492422) (Subject)

    11/22/24 8:47:59 AM ET
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Bluejay Diagnostics Inc.

    SC 13G - Bluejay Diagnostics, Inc. (0001704287) (Subject)

    11/14/24 5:49:49 PM ET
    $BJDX
    Medical/Dental Instruments
    Health Care